Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Observational, Open-Label, Single-Arm Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Next Previous
Trial Profile

A Multicenter, Observational, Open-Label, Single-Arm Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms STRIVE
  • Sponsors Biogen

    • Most Recent Events

    • 13 Oct 2023 Results assessing the effect of natalizumab on CGM and thalamic atrophy over 2 years (from MRI scans of NTZ-treated (n=94) patients from the STRIVE study) compared with a historical placebo in patients (n=63) with early relapsing remitting multiple sclerosis (from the dimethyl fumarate DEFINE trial), presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis.
    • 26 Mar 2023 Results of post hoc analysis assessing the effectiveness and safety of natalizumab in patients who self-identified as either Black/African American (AA) or Hispanic/Latino, published in the Neurology and Therapy.
    • 05 Sep 2022 Results assessing effects of natalizumab on cognitive processing speed, confirmed disability improvement (CDI), and patient-reported outcomes , published in the CNS Drugs.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top